The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases

Retrospective case‐control (n=104; 46 ≥65 years) found no difference in attained infliximab exposure and endoscopic remission in elderly and nonelderly patients, suggesting the same infliximab trough concentration target can be used in therapeutic drug monitoring.

British Journal of Clinical Pharmacology